Article info
PDFHepatology
Original research
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis
- Correspondence to Dr Samuel Anthony Lachlan Hall, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Australia; sammy.hall86{at}gmail.com
Citation
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis
Publication history
- Received December 30, 2020
- Accepted August 25, 2021
- First published September 7, 2021.
Online issue publication
November 15, 2022
Article Versions
- Previous version (15 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.